National Kidney Foundation Statement on CREDENCE Data as Potential New Treatment for Diabetic Kidney Disease

[In The News]

NEW YORK, April 14, 2019 /PRNewswire/ -- "Data from the CREDENCE trial published today in the New England Journal of Medicine demonstrate that INVOKANA® (Canagliflozin) can help reduce the risk of end stage renal disease (ESRD) and cardiovascular events in patients already diagnosed with...

View the full article